Shots:

• AstraZeneca's Imfinzi durvalumab (1500mg- fd- q4w) is recommended for approval in the EU for an additional dosing option in the approved indication of LA- unresectable NSCLC in adults whose tumors express PD-L1 on at least 1% of tumor cells and whose disease has not progressed following platinum-based CRT
• The CHMP opinion is based on P-III PACIFIC trial that supported the 2wk- weight-based dosing of 10mg/kg q2w already approved in LA- unresectable NSCLC & the P-III CASPIAN trial which used fd- q4w during maintenance treatment in ES-SCLC
• The option would extend dosing from two to four weeks- reducing medical visits and improving patient convenience

 ­ Ref: AstraZeneca | Image: New Europe